Colchicine, a common drug to treat gout, is being evaluated to treat COVID-19 and shows significant reduction in inflammation and lung injury in pre-clinical studies

Death in COVID-19 patients has actually been linked to the cytokine storm, where the body produces excessive pro-inflammatory particles (cytokines) that ultimately lead to ARDS and potentially death. Full research study outcomes are readily available in preprint and support the continuation of the COLCORONA trial.

The double-blind, placebo-controlled, randomized COLCORONA trial featuring a generic immunomodulator (colchicine) passed its futility analysis in June 2020 with an independent Data Safety Monitoring Board, enabling continued enrollment. Colchicine, which is already available for treatment of gout, pericarditis, and Familial Mediterranean Fever, would be a cost effective orally administered treatment alternative if outcomes prove positive..

Unlike most other research studies, this research study does not include leaving your house. The study staff will call you straight via phone or video-visits for follow-up. Medication or a placebo (a pill without any active components) will be provided to your house at no cost.If you have an interest in signing up with, the study personnel will figure out if you are eligible to join. This research study is among the couple of registering newly detected patients with moderate to moderate signs who are not hospitalized and over the age of 40 (and hires clients past the age of 70). Involvement in the research study lasts 30 days. When the research study is completed, the results will be announced, however will not include your recognizing information.Patients and physicians thinking about COLCORONA can call the research study hotline at 1-877-536-6837, 24/7 or visit www.colcorona.net. If you have actually recently been detected with COVID-19 and you are interested in taking part in the COLCORONA trial, do not postpone calling the hotline number.

The COLCORONA trial hires recently diagnosed, non-hospitalized adult clients with COVID-19 for participation in a totally free, at-home clinical trial developed to minimally problem patients. Full research study outcomes are available in preprint and support the extension of the COLCORONA trial.

What Patients Need to Know About the COLCORONA Trial to Enroll.

” At the minute, there is no readily available, FDA-approved treatment that can be provided to patients in your home to avoid them from getting worse health problem, hospitalization and death from COVID-19 problems. It is extremely crucial for us to discover therapies that we can provide to clients now,” stated Dr. Norman Lepor, Director of Clinical Research for Westside Medical Associates of Los Angeles and COLCORONA main investigator for Los Angeles.

About the COLCORONA Trial.

Unlike many other research studies, this study does not involve leaving your home. If you have actually recently been detected with COVID-19 and you are interested in getting involved in the COLCORONA trial, do not delay calling the hotline number.

MONTREAL, July 27, 2020 / PRNewswire/– Montreal Heart Institute (MHI) today revealed that the COLCORONA scientific trial has actually increased registration capability in the United States ( Los Angeles, San Francisco, Houston, Dallas, Miami, Gainesville, New York, New Jersey, Connecticut) as the favorable case numbers of COVID-19 continue to rise. The COLCORONA trial hires recently diagnosed, non-hospitalized adult patients with COVID-19 for participation in a free, at-home clinical trial created to minimally burden clients. The largest trial of its kind, this at-home, contactless trial continues to likewise register in Canada, Spain and South Africa with more sites constantly added.

” Our current lead to pre-clinical research studies reveal the capacity of colchicine to minimize the inflammatory storm and lung damage likewise seen in clients with COVID-19,” said Dr. Jean-Claude Tardif, Director of the Research Center at MHI, Professor of Medicine at the University of Montreal, and COLCORONA principal detective. “We are dedicated to consisting of a large number of patients worldwide in this robust research study to determine the capability of colchicine to keep clients out of the healthcare facility, off ventilators and ultimately save lives.”

COLCORONA is a contact-free, at-home, randomized, double-blind, placebo-controlled study lack numerous areas in Canada, the United States, Europe, South America, and South Africa. COLCORONA is collaborated by the Montreal Health Innovations Coordinating Center (MHICC) and moneyed by the Government of Quebec, the Bill & & Melinda Gates Foundation, the National Heart, Lung, and Blood Institute (NHLBI) of the United States National Institutes of Health (NIH), and Sophie Desmarais Montréal benefactor, daughter of the late company mogul, Paul Desmarais Sr., Pharmascience, CGI, and DACIMA are likewise collaborators of COLCORONA.

To learn more about the study, go to www.colcorona.net.